Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2004-09-24
2009-10-27
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S188100, C424S208100
Reexamination Certificate
active
07608271
ABSTRACT:
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
REFERENCES:
patent: 4652629 (1987-03-01), Patrick et al.
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5614487 (1997-03-01), Battersby et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6103236 (2000-08-01), Suzawa et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6258782 (2001-07-01), Barney et al.
patent: 7090851 (2006-08-01), Bridon et al.
patent: 2005/0065075 (2005-03-01), Erickson et al.
patent: 2008/0176794 (2008-07-01), Bridon et al.
patent: 2008/0199483 (2008-08-01), Bridon et al.
patent: 0 602 290 (1994-06-01), None
patent: 0 602 290 (1999-08-01), None
patent: 1 264 840 (2002-12-01), None
patent: WO 95/10302 (1995-04-01), None
patent: WO 96/19495 (1996-06-01), None
patent: WO 99/24074 (1999-05-01), None
patent: WO 99/24075 (1999-05-01), None
patent: WO 99/48536 (1999-09-01), None
patent: WO 00/69902 (2000-11-01), None
patent: WO 00/76550 (2000-12-01), None
patent: WO 00/76551 (2000-12-01), None
patent: WO 2005/108418 (2005-11-01), None
Tolman, R. L., et al., 1993, Cyclic V3-loop-related HIV-1 conjugate vaccines: Synthesis, conformation and immunological properties, Int. J. Peptide Protein Res. 41:455-466.
U.S. Appl. No. 09/657,336, filed Sep. 2000, Bridon et al.
U.S. Appl. No. 09/623,533, filed Sep. 2000, Bridon et al.
Archakov, Alexander I. et al. (2003) “Protein-protein interactions as a target for drugs in proteomics” Proteomics 3: 380-391.
Davies, David R. and Gerson H. Cohen (Jan. 1996) “Interactions of protein antigens with antibodies” Proc. Natl. Acad. Sci. 93: 7-12.
Jiang, Shibo et al. (2002) “Peptide and Non-peptide HIV Fusion Inhibitors” Current Pharmaceutical Design 8: 563-580.
Jones, Susan and Janet M. Thornton (Jan. 1996) “Principles of protein-protein interactions” Proc. Natl. Acad. Sci. 93: 13-20.
Kuiken C, Foley B, Hahn B, Marx P. McCutchan F, Mellors J, Wolinsky S, and Korber B, editors.HIV Sequence Compendium 2001, Published by Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2002: 288-289.
Kwong, P.D. et al. (Feb. 2000) “Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus” J. Virol. 74(4): 1961-1972.
Lawless, Mary K. et al. “HIV-1 Membrane Fusion Mechanism: Structural Studies of the Interactions between Biologically-Active Peptides from gp41”Biochemistry35, 1996: 13697-13708.
Sanders, R.W. et al. (Sep. 2002) “Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1”. J. Virol. 76(17): 8875-8889.
Wang et al. (Apr. 1995) “Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype” J. Virol. 69(4): 2708-2715.
Wild, Carl. T. et al. (Oct. 1994) “Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection” Proc. Natl. Acad. Sci. USA 91: 9770-9774.
Yang, X. et al. (May 2000) “Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution” J. Virol. 74(10): 4746-4754.
Proc. Natl. Acad. Sci., 1996, 93 (5), 2186-2191.
Anti-Cancer Drugs, 1988, 8, 677-685.
Pending U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, Bridon, et al.
Pending U.S. Appl. No. 09/657,336, filed Sep. 7, 2000, Bridon, et al.
Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, and Korber B, editors.HIV Sequence Compendium 2001, Published by Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2002: 288-289.
Kwong, P.D. et al., (2000) “Oligomeric Modeling and Electrostatic Analysis of the gp 120 Envelope Glycoprotein of Human Immunodeficiency virus”J. Virol. 74(4):1961-1972.
Lambert, D.M. et al., (1996) “Peptides from Conserved Regions of Pararayxovirus Fusion (F) Proteins are Potent Inhibitors of Viral Fusion”Proc. Natl. Acad. Sci., 93 (5):2186-2191.
Lawless, Mary K. et al. (1996) “HIV-1 Membrane Fusion Mechanism: Structural Studies of the Interactions between Biologically-Active Peptides from gp41”Biochemistry35: 13697-13708.
Sanders, R. W. et al., (2002) “Stabilization of Soluble, Cleaved, Trimerio Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1”J. Virol. 76(17):8875-8889.
Stehle, G. et al., (1997) “The loading rate determines tumor targeting properties of methotrexato-albumin conjugates in rats”Anti-Cancer Drugs, (8):677-685.
Wang, et al., (1995) “Sequence Diversity of V1 and V2 Domains of gp 120 from Immunodeficiency Virus Type 1: Lack of Correlation with Viral Phenotype”J. Virol. 69(4):2708-2715.
Yang, X. et al., (2000) “Modification that Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Primers in Solution”J. Virol. 74(10):4746-4754.
Christophe Boeckler, “Immunogenicity of New Heterobifunctional Cross-Linking Reagents Used in the Conjugation . . . ”, Journal of Immunological Methods, 1996, vol. 191, pp. 1-10.
Carl Wild, “A synthetic Peptide Inhibitor of Human Immunodeficiency Virus Replication : Correlation . . . ”, Proc. Natl. Acad. Sci., Nov. 1992, vol. 89, pp. 10537-10541.
Joseph G. Sodroski, “HIV-1 Entry Inhibitors in the Side Pocket”, Cell, Oct. 29, 1999, vol. 99, pp. 243-246.
Aran F. Labrijn, “Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 . . . ” Journal of Virology, Oct. 2003, vol. 77, pp. 10557-10565.
Nasar M. Qureshi, “Characterization of a Putative Cellular Receptor for HIV-1 Transmembrane Glycoprotein Using Synthetic Peptides” AIDS, 1990, vol. 4, pp. 553-558.
Tolman, R.L. et al. (1993) “Cyclic V3-Loop-Related HIC-1 Conjugate Vaccines: Synthesis, Conformation and Immunological Properties”Int. J. Peptide Protein Res.41:455-466.
Chen, Chin-Ho et al. (Jun. 1995) “A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion,” Journal of Virology, 69(6): 3771-3777.
Shugars, Diane C. et al. (May 1996) “Biophysical Characterization of Recombinant Proteins Expressing the Leucine Zipper-Like Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41,” Journal of Virology, 70(5): 2982-2991.
U.S. Appl. No. 10/950,010, filed Sep. 24, 2004, Bridon et al.
Archakov, Alexander I. et al. (2003) “Protein-Protein Interactions as a Target for Drugs in Proteomics,” Proteomics, 3:380-391.
Boeckler, Christophe “Immunogenicity of New Heterobifunctional Cross-Linking Reagants Used in the Conjugation . . . ”, Journal of Immunological Methods, (1996), vol. 191 pp. 1-10.
Chen, Chin-Ho et al. (Jun. 1995) “A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion,” Journal of Virology, 69(6): 3771-3777.
Christodoulou, John et al. “H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys34”,FEBS Letters376:pp. 1-5 (1995).
Davies, David R. et al. (Jan. 1996) “Interactions of Protein Antigens with Antibodies,” Proc. Natl. Acad. Sci. USA, 93:7-12.
Jiang, Shibo et al. (2002) “Peptide and Non-peptide HIV Fusion Inhibitors,” Current Pharmaceutical Desi
Boudjellab Nisssab
Bridon Dominique P.
Dufresne Robert S.
Milner Peter G.
Robitaille Martin
Conjuchem Biotechnologies Inc.
Lando & Anastasi LLP
Parkin Jeffrey S.
LandOfFree
Modified human immunodeficiency virus anti-fusogenic GP41... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified human immunodeficiency virus anti-fusogenic GP41..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified human immunodeficiency virus anti-fusogenic GP41... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4122687